IDO2 and neoplasm: Tumor immunity encompasses many types of negative immune regulators released in the tumor microenvironment, including PD-1, lymphocyte-activation gene −3, and indoleamine 2,3-dioxygenase (Chen et al., 2024), which should be further investigated.